BioNTech/Pfizer also made the same statement about its own vaccine the day before. Following BioNTech/Pfizer, the United States (USA)-based biotechnology company Moderna has also started the clinical research process of a new coronavirus vaccine made suitable for the Omicron variant.
In the statement made by Moderna, it was reported that the vaccine in question will be tested in people older than 18 years of age, and this study will be conducted in two groups, one for people who have received two doses of Moderna vaccine to date, and the other for people who have had the reminder vaccine on top of two vaccines.
In the statement, it was emphasized that for the test phase to be carried out in 24 different regions of the USA, approximately 300 subjects per group will be studied.
BioNTech/Pfizer and Moderna started work on developing a new vaccine suitable for the Omicron variant, after it was determined that the currently used vaccines on the market were less effective against the Omicron variant.
On the other hand, Moderna also announced the results of its scientific research on the effect of the currently used vaccine against the Omicron variant. Accordingly, when the reminder dose is taken with the Moderna vaccine, the number of antibodies formed in the body decreases to one-sixth six months after vaccination.
Moderna CEO, Stephane Bancel, described it as “relaxing” to still have antibodies in the body six months after the reminder dose was given, regarding these data obtained as a result of tests on 20 people.
Reuters,AFP / ET,SSB
© Deutsche Welle English